Medical News

RSS

Mazor Robotics introduces next-generation spinal surgical guidance system

Mazor Robotics Ltd., the leader in innovative surgical robots and complementary products for spine surgery, introduced today Renaissance, the next-generation of the world's only spinal robotic surgical guidance system.

6 Jun 2011

VHA honors Medical Action with 2011 service excellence award

Medical Action Industries Inc., a leading supplier of medical and disposable surgical products today announced that VHA Inc., the national health care network, honored Medical Action Industries as the Non-Pharmacy Supplier of the Year at its Annual Leadership Conference, May 15-17, in San Diego, Calif. Medical Action is a long-time supplier of Novation, VHA's health care supply contracting company.

6 Jun 2011

PING, HP partner to reduce malaria through mobile health monitoring technology

On the heels of the United Nations Social Innovation Summit, HP and nonprofit organization Positive Innovation for the Next Generation (PING) are launching a collaboration to improve the quality and efficiency of disease surveillance in Botswana through mobile health monitoring technology that can enhance protection and prevention against major malaria outbreaks.

6 Jun 2011

First Edition: June 6, 2011

Kaiser Health News staff writer Christopher Weaver reports: "Short on cash and time, officials in California and at least a dozen other states have turned to philanthropies to help pay for the extra work required under the federal health law".

6 Jun 2011

FDA grants orphan drug designation for Aradigm's ciprofloxacin to manage bronchiectasis

Aradigm Corporation today announced it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for ciprofloxacin for inhalation for the management of bronchiectasis (BE).

6 Jun 2011

Positive data from Biogen Idec's AVONEX clinical trial on multiple sclerosis presented at CMSC 2011

Biogen Idec today announced the findings from a randomized, multicenter, dose-blinded clinical trial that evaluated the effect of AVONEX dose titration, or gradual dose escalation, on flu-like symptoms associated with the therapy.

6 Jun 2011

Constellation raises $15M in Series B extension financing

Constellation Pharmaceuticals, Inc., a leading biopharmaceutical company in the field of epigenetics, today announced that it has raised $15 million in a Series B extension financing. All major current investors participated in the round, including Third Rock Ventures, The Column Group, Venrock Associates, SR One and Altitude Life Science Ventures.

6 Jun 2011

Amylin's metreleptin clinical study data on partial lipodystrophy presented at ENDO 2011

Amylin Pharmaceuticals, Inc. today announced results from a study that showed treatment with metreleptin, an investigational treatment that is an analog of the human hormone leptin, improved diabetes and lipid control in patients with partial lipodystrophy.

6 Jun 2011

New gene therapy may cure Type 1 diabetes

An experimental cure for Type 1 diabetes has a nearly 80 percent success rate in curing diabetic mice. The results, to be presented Saturday at The Endocrine Society's 93rd Annual Meeting in Boston, offer possible hope of curing a disease that affects 3 million Americans.

6 Jun 2011

Light exposure can enhance brain's visual circuits

Any parent knows that newborns still have a lot of neurological work to do to attain fully acute vision. In a wide variety of nascent animals, genes provide them with only a rough wiring plan and then leave it to the developing nervous system to do its own finish work.

6 Jun 2011

Cancer risk assessment in Lynch syndrome

Among various genetic mutations for individuals with Lynch syndrome, a hereditary cancer syndrome that carries a high risk of colon cancer and an above-normal risk of other cancers, researchers have identified mutations associated with a lower cancer risk and mutations associated with an increased risk for ovarian and endometrial cancer, according to a study in the June 8 issue of JAMA, a theme issue on cancer.

6 Jun 2011

New UH Seidman Cancer Center center to offer latest treatments and technology

University Hospitals (UH) Seidman Cancer Center, Northeast Ohio's first and only freestanding cancer hospital, opens to patients on June 6. The ten-story, 150-bed cancer hospital will house the latest cancer-fighting treatments and technology – all in a patient-centered, healing-focused environment.

6 Jun 2011

Global gene therapy market to reach $300 million by 2015

The global gene therapy market is expected to grow to over $300 million by 2015, according to a new report available on companiesandmarkets.com. The gene therapy market will grow further driven by the human genome project, the increasing incidence of cancer and other critical diseases.

6 Jun 2011

JDRF praises New Brunswick government for comprehensive diabetes strategy

The Juvenile Diabetes Research Foundation (JDRF) applauds the New Brunswick government for its commitment to diabetes.

6 Jun 2011

New blog aims to help dispel many myths behind cervical smear test

In the UK, 20 per cent of women still do not attend smear tests, putting themselves at risk of leaving pre-cancerous cervical cells undetected. A new blog, entitled, 'my diary from down under', aims to help dispel many of the myths surrounding having a smear with the aim of putting women at ease and encouraging more women to attend their cervical screens when invited.

6 Jun 2011

Chiasma presents Octreolin pharmacology data from clinical studies at International Pituitary Congress

Chiasma, Inc., a privately held biopharma company, presented pharmacology results from clinical studies at the 12th International Pituitary Congress showing that Octreolin, a proprietary investigational new oral formulation of octreotide, demonstrated a consistent pharmacokinetic (PK) profile similar to that of subcutaneously injected octreotide acetate.

6 Jun 2011

Crystal Research Associates report now available in MedPro website

MedPro Safety Products, Inc., a leading developer of transformational technologies that enable safer medication delivery and blood collection, today announced the availability of a recently published research report prepared for the Company by Crystal Research Associates.

6 Jun 2011

GTx to initiate two Ostarine Phase III trial for treatment of muscle wasting in patients with NSCLC

Following the conclusion of a series of meetings with the United States Food and Drug Administration (FDA), GTx, Inc. announced today the clinical trial design for the two Phase III Ostarine registration studies for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer (NSCLC).

6 Jun 2011

Avantra announces Rapid Assay Prototyping Service for researchers and clinicians

Avantra Biosciences, a leading innovator in protein diagnostics, announces a Rapid Assay Prototyping Service. Avantra's new service allows researchers to cost effectively accelerate their research efforts using custom designed biomarker assays developed on Avantra's proven QPDx BioChip platform.

6 Jun 2011

United Therapeutics completes oral treprostinil Phase 3 trial on pulmonary arterial hypertension

United Therapeutics Corporation announced today the completion of its FREEDOM-M Phase 3 trial of treprostinil diethanolamine, an investigational sustained release oral formulation of treprostinil, a stable synthetic form of prostacyclin, in patients with pulmonary arterial hypertension (PAH).

6 Jun 2011